Green Tea Polyphenol (-)-Epicatechin Pretreatment Mitigates Hepatic Steatosis in an In Vitro MASLD Model

Area of Science:

• Hepatology
• Metabolic Disorders
• Pharmacology

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern linked to obesity and type 2 diabetes.
• Current treatments for MASLD are limited, necessitating research into novel therapeutic agents.
• (-)-epicatechin (EPI) is being investigated for its potential role in managing liver conditions.

Purpose of the Study:

• To evaluate the efficacy of (-)-epicatechin (EPI) in an in vitro model of MASLD.
• To determine EPI's effects on HepG2 cell metabolic viability, PPARα, PPARγ, and glutathione (GSH) levels.

Main Methods:

• An in vitro MASLD model was established using HepG2 cells exposed to oleic acid.
• Cells were pretreated with varying concentrations of EPI (10-100 μM).
• Metabolic viability (MTS assay), PPARα/γ levels (ELISA), lipid accumulation (Oil Red O), and GSH levels were assessed.

Main Results:

• EPI pretreatment significantly increased metabolic viability in oleic acid-induced MASLD HepG2 cells (74-86% vs. 71%).
• EPI demonstrated a dose-dependent decrease in PPARα, PPARγ, and GSH levels.
• EPI modulated key markers related to lipid metabolism and oxidative stress in vitro.

Conclusions:

• (-)-epicatechin exhibits significant hepatoprotective effects in an in vitro MASLD model.
• EPI's modulation of PPARα, PPARγ, and GSH suggests a role in managing MASLD pathogenesis.
• EPI warrants further investigation as a potential therapeutic agent for MASLD.